Quel est le prix pour Vaxil Bio Ltd. (VXL)

Le prix pour Vaxil Bio Ltd. (VXL) est $0.1174299

Quelle est la capitalisation boursière pour Vaxil Bio Ltd. (VXL)

La capitalisation boursière pour Vaxil Bio Ltd. (VXL) est $467.84K

Vaxil Bio Ltd. (VXL) Prix et Capitalisation Boursière

Vaxil Bio Ltd. is a biotechnology firm dedicated to discovering and developing innovative therapeutic agents. Its foundation lies in a unique signal peptide-based platform, which it leverages to address critical health challenges, specifically infectious diseases and various cancers. The company's primary therapeutic candidate, ImMucin, has successfully advanced through Phase I/II clinical trials as a potential treatment for multiple myeloma. Beyond ImMucin, Vaxil Bio is actively developing a vaccine/treatment for tuberculosis, as well as a vaccine targeting coronavirus (COVID-19). Strategic alliances bolster its research efforts; Vaxil Bio collaborates with The Tel Aviv Sourasky Medical Center on a research initiative to create a peptide-based COVID-19 vaccine. Furthermore, it holds a Cooperative Research and Development Agreement with the U.S. Army Medical Research Institute of Infectious Diseases to assess CorVax's efficacy in preventing COVID-19 in murine models. Established in 2006, the company's operations are based in Toronto, Canada.

Prix pour VXL	L’actif B	La capitalisation boursière de B	Résultats
$1,372,870 $467.84K	NVDA	$5.470T	+1,169,097,139.93%
$1,121,248 $467.84K	AAPL	$4.467T	+954,822,926.42%
$1,047,783 $467.84K	GOOG	$4.174T	+892,262,423.35%
$928,730 $467.84K	MSFT	$3.700T	+790,880,289.83%
$716,448 $467.84K	AMZN	$2.854T	+610,107,062.11%

Prix pour VXL

L’actif B

La capitalisation boursière de B

Résultats

$1,372,870 $467.84K